47results about How to "Sequence stability" patented technology

The invention belongs to the field of molecular biology and relates to a high-activity T-cell promoter and an application thereof. Particularly, the high-activity T-cell promoter comprises an element 1 and an element 2, wherein the element 1 is an EF1 alpha promoter and/or an EF1 alpha promoter containing an intron; and the element 2 is any one or more of an mCMV promoter, an hCMV promoter and a CD3e promoter. The high-activity T-cell promoter provided by the invention can be used for efficiently expressing a foreign gene in a T cell, has a stable sequence and is free from sequence loss during the transfer process of a prokaryotic cell and a eukaryotic cell. The high-activity T-cell promoter is applicable to driving the high-efficiency expression of the foreign gene, especially a full-length antibody gene, in the T cell during the process of adoptive cellular immunotherapy.

The present invention discloses a nucleic acid aptamer, wherein the sequence of the nucleic acid aptamer comprises a DNA segment represented by any one sequence selected from a sequence 1, a sequence 2 and a sequence 3. The nucleic acid aptamer can further be various similar sequences with high homology or a derivative obtained from the sequence of the present invention. The invention further discloses a nucleic acid aptamer screening method, which comprises: synthesizing a random single-stranded DNA library and primers, carrying out SELEX screening, carrying out PCR amplification of library, preparing a DNA single strand library, and finally carrying out repeated screening, negative screening and multi-round screening to obtain the nucleic acid aptamer. The nucleic acid aptamer and the derivative thereof can be used in recognition of the prostate cancer cell strain PC-3 or preparation of kits, molecular probes and targeted mediums for prostate cancer detection, and can further be used in design and preparation of prostate cancer treatment drugs. Compared with the protein antibody, the nucleic acid aptamer of the present invention has advantages of high affinity, high specificity, no immunogenicity, capability of being chemically synthesized, small molecular weight, stability, easy storage, easy labeling and the like.

The invention discloses a nucleic acid aptamer for recognizing liver cancer cells, and a screening method and a purpose thereof. The nucleotide sequence of the nucleic acid aptamer comprises the feature sequence part shown as Seq ID No.1. The purpose comprises the purpose of the nucleic acid aptamer to the design and preparation of anti-liver-cancer medicine or detection reagents. The detection reagents comprise enzyme-linked immunosorbent assay, immunoradiometric assay or fluorescence method. The invention also comprises a target preparation and a medicine composition. The target preparationcomprises the nucleic acid aptamer and a medically acceptable carrier or a shaping agent. The medicine composition comprises the nucleic acid aptamer, at least one antitumor medicine and a medically acceptable carrier. Compared with the prior art, the nucleic acid aptamer can be used for specifically recognizing the liver cancer cells; good application prospects are realized.

A nucleic acid aptamer used for detecting human uveal melanoma cells (OCM-1) and applications thereof in preparation of detection preparations are disclosed. Compared with the prior art, the nucleic acid aptamer and the applications are advantageous in that the prepared nucleic acid aptamer can specifically recognize the uveal melanoma cells, has good affinity, no immunogenicity, and a small molecular weight, and can be chemically synthesized in vitro; and different positions of the nucleic acid aptamer can be modified and substituted. In addition, the nucleic acid aptamer has advantages of astable sequence, capability of being convenient to store and mark, and the like. When the nucleic acid aptamer is adopted for detecting the human uveal melanoma cells, operation is simpler and rapider. The nucleic acid aptamer has a synthesis cost lower than antibody preparing costs, a short period and good reproducibility.

The invention belongs to the field of the molecular biology and relates to a cancer cell broad spectrum high-activity promoter and the usage thereof. The cancer cell broad spectrum high-activity promoter can express exogenous genes in cancer cells with broad spectrums efficiently. The expressive activity of the promoter in a series of cancer cells is higher than the existing CAG promoters and is stable in the sequence (it does not have sequence loss in the transfer process of the prokaryotic cell and the eukaryotic cell). The cancer cell broad spectrum high-activity promoter can be applied to the oncogene therapeutic process to drive the exogenous genes to be expressed efficiently in the cancer cells.

The invention discloses an ssDNA nucleic acid aptamer and application thereof to detect pathogenic vibrio alginolyticus. The nucleotide sequence of the ssDNA nucleic acid aptamer is 5'-GACGCTTACTCAGGTGTGACTCGCGTTTTATTGGTGTGGGGCTGGGGCGGTGGGTGGCTCTACTGGTTCCGTTCGAAGGACGCAGATGAAGTCTC-3'(SEQ ID NO:1). The ssDNA nucleic acid aptamer is specific for and highly sensitive to the trachinotus ovatus source pathogenic vibrio alginolyticus, and has no immunogenicity. The ssDNA nucleic acid aptamer is stable in structure and easy to modify, facilitates synthesis and preservation, and can rapidly and accurately detect and diagnose the trachinotus ovatus source pathogenic vibrio alginolyticus.

The invention discloses an ssDNA aptamer capable of specifically recognizing a GTONNV (Guangxi trachinotus ovatus nervous necrosis virus) and an application of the aptamer. The nucleotide sequence ofthe ssDNA aptamer is 5'-GTCTGAAGTAGACGCAGGAGCCTTTCGTGTTTCATTAGTGTGTTTCCATTGGGCGGCTCGGGGCAAAAGGAGTCACACCTGAGTAAGCGT-3'(SEQ ID NO: 1) or 5'-CCTTTCGTGTTTCATTAGTGTGTTTCCATTGGGCGGCTCGGGGCAAAAGG-3'(SEQ ID NO: 2). The ssDNA aptamer has specificity and high sensitivity to GTONNV infected cells and has no immunogenicity. The ssDNA aptamer has high specificity and high affinity, and is free of cytotoxicity,stable, easy to modify and convenient to synthesize and preserve, and the GTONNV infected cells can be detected and diagnosed rapidly and accurately.

According to the nucleic acid aptamer ZQ-2 for targeting human highly invasive choroidal melanoma and the application thereof, through property characterization of the nucleic acid aptamer ZQ-2 and identification of target molecules, tumor markers of choroidal melanoma can be found, and the nucleic acid aptamer ZQ-2 is used for diagnosis and treatment and targeted therapy of choroidal melanoma and has a wide application prospect. The prepared nucleic acid aptamer can specifically recognize human highly invasive choroidal melanoma cells and choroidal melanoma tissues and has very high affinity; there is no immunogenicity; the molecular weight is small, and in-vitro chemical synthesis can be realized; different parts of the aptamer are easy to modify and replace. Meanwhile, the gene has the advantages of stable sequence, convenience in storage, convenience in marking and the like. When the nucleic acid aptamer is used for detecting human choroidal melanoma cells, the operation is simpler and quicker, the synthesis cost of the nucleic acid aptamer is lower than that of antibody preparation, the period is short, and the reproducibility is good.

The invention relates to an aptamer PZ-1 targeting human highly invasive choroidal melanoma and application. Through property characterization of the nucleic acid aptamer PZ-1 and identification of target molecules, tumor markers of choroidal melanoma can be found, and the nucleic acid aptamer PZ-1 is used for diagnosis and treatment and targeted therapy of choroidal melanoma. The prepared nucleic acid aptamer can specifically recognize human highly invasive choroidal melanoma cells and choroidal melanoma tissues and has very high affinity; there is no immunogenicity;the molecular weight is small, and in-vitro chemical synthesis can be realized; different parts of the aptamer are easy to modify and replace. Meanwhile, the invention has the advantages of stable sequence, convenience in storage, convenience in marking and the like. When the nucleic acid aptamer is used for detecting human choroidal melanoma cells, the operation is simpler and quicker, the synthesis cost of the nucleic acid aptamer is lower than that of antibody preparation, the period is short, and the reproducibility is good.

The invention relates to a nucleic acid aptamer QQ-4 targeting human highly invasive choroidal melanoma and application. By identifying the property characterization and target molecules of the nucleic acid aptamer QQ-4, a tumor marker of the choroidal melanoma can be found, and the nucleic acid aptamer QQ-4 is used for diagnosis and treatment and targeted treatment of the choroidal melanoma. The prepared nucleic acid aptamer can specifically recognize human highly invasive choroidal melanoma cells and choroidal melanoma tissues and has high affinity; the nucleic acid aptamer has no immunogenicity; the molecular weight is small, and in-vitro chemical synthesis can be achieved; and different parts of the nucleic acid aptamer are easy to modify and replace. Meanwhile, the nucleic acid aptamer has the advantages of being stable in sequence, convenient to store, convenient to mark and the like. When the nucleic acid aptamer is adopted for detecting the human choroidal melanoma cells, operation is easier and faster, the synthesis cost of the nucleic acid aptamer is lower than the cost of antibody preparation, the period is short, and reproducibility is good.

The invention relates to a nucleic acid aptamer QQ-2 targeting human highly invasive choroidal melanoma and application. By identifying the property characterization and target molecules of the nucleic acid aptamer QQ-2, a tumor marker of the choroidal melanoma can be found, and the nucleic acid aptamer QQ-2 is used for diagnosis and treatment and targeted treatment of the choroidal melanoma. The prepared nucleic acid aptamer can specifically recognize human highly invasive choroidal melanoma cells and choroidal melanoma tissues and has high affinity; the nucleic acid aptamer has no immunogenicity; the molecular weight is small, and in-vitro chemical synthesis can be achieved; and different parts of the nucleic acid aptamer are easy to modify and replace. Meanwhile, the nucleic acid aptamer has the advantages of being stable in sequence, convenient to store, convenient to mark and the like. When the nucleic acid aptamer is adopted for detecting the human choroidal melanoma cells, operation is easier and faster, the synthesis cost of the nucleic acid aptamer is lower than the cost of antibody preparation, the period is short, and reproducibility is good.

The invention discloses a nucleic acid aptamer for recognizing extracellular vesicles of an ovarian cancer drug-resistant patient and application of the nucleic acid aptamer, and belongs to the technical field of biology. The nucleic acid aptamer obtained through cell screening has high affinity and specificity and low immunogenicity, can be chemically synthesized in vitro, is low in cost and small in molecular weight, can modify and replace different parts of the nucleic acid aptamer, and is stable in sequence and easy to store. The nucleic acid aptamer can be used for preparing anti-tumor drugs, ovarian cancer drug-resistant cell strains or ovarian cancer drug-resistant patient serum exosome detection kits or ovarian cancer drug-resistant patient serum exosome detection probes.